BOOST Pharma

Executive Summary

BOOST Pharma is a Danish biotechnology company developing BT-101, a first-in-class stem cell therapy for Osteogenesis Imperfecta (OI), a rare genetic bone disorder with no approved curative treatments. Positive Phase I/II results demonstrated safety and efficacy signals, positioning BT-101 as a potential breakthrough. The company is now advancing toward a pivotal Phase III study, which if successful, could address a significant unmet need in the OI patient population. With orphan drug designation and strong preliminary data, BOOST Pharma represents a high-potential investment opportunity in the cell and gene therapy space.

Upcoming Catalysts (preview)

• Q3 2026Initiation of Pivotal Phase III Trial80% success
• Q2 2026Regulatory Guidance from FDA/EMA on Phase III Design90% success
• Q4 2026Orphan Drug Designation Expansion or Fast Track Status70% success